Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer
Status:
Recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
It suggests in the Guideline that the postmenopausal women with breast cancer who have taken
selective estrogen receptor modulators (SERMs) therapy for 2-3 years could benefit from
changing endocrine therapy to aromatase inhibitors (AIs). This is a prospective, randomized
and non-inferior trial to evaluate the prognosis of changing endocrine therapy from SERMs to
AIs in perimenopausal and recently postmenopausal women with early-stage hormone
receptor-positive breast cancer.